Obesity, a leading cause of human morbidity and mortality, is one of the major global health challenges of the 21st century. It significantly increases the risk of type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease and certain forms of cancer. New and emerging medicines have shown unprecedented efficacy in promoting weight loss and reducing the risk of many of these diseases.

This meeting aims to integrate existing knowledge with the latest discoveries informing the mechanisms of obesity drug action, exploring potential health benefits beyond weight loss. The program will cover new biological discoveries in the field, including those related to glucagon and amylin, and leveraging the role of enteroendocrine cell secretion. The program will also highlight cutting-edge drug discovery approaches and the clinical relevance of basic science discoveries to obesity research. We will explore how to improve the quality of weight loss, by minimizing side effects and preserving muscle mass and function, as well as advances in diverse combination therapies.

Additionally, this conference will be held jointly with the Keystone Symposium on “Cardiometabolism in Health and Disease,” to enable better understanding of the intersection of these diseases, and their treatments. This pairing provides an opportunity for cross-disciplinary insights and collaborations towards novel research directions and greater clinical impacts across both fields.